ND-2110
ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM) . ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations, . ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models[1].
Product Specifications
CAS Number
1388894-17-4
UNSPSC
12352005
Target
IRAK
Type
Reference compound
Related Pathways
Immunology/Inflammation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/nd-2110.html
Smiles
O=C(N)C[C@H]1CCC2=C1C3=C(O[C@@H]4CC[C@@H](N5CCOCC5)CC4)N=CN=C3S2
Molecular Formula
C21H28N4O3S
Molecular Weight
416.54
References & Citations
[1]Kelly PN, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015 Dec 14;212 (13) :2189-201.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb1237400 0.1 mg
Roledumab (RHD) - Research Grade Biosimilar Antibody
Sign In for Pricing
View Details LV777447 1.0 µg DNA
RPL21P8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)
Sign In for Pricing
View Details 